The FDA enforcement report lists a Class II recall of vancomycin injection 1 g in 200 mL of 5% dextrose in single-dose GALAXY containers, made by Baxter Healthcare. The stated reason is deviations from current good manufacturing practice, and the recall is listed as ongoing, dated 9 September 2026.
Class II means use may cause temporary or medically reversible harm, or that serious harm is remote. The report names no specific defect or reported harm.
The product is a ready-to-infuse bag used in hospitals. Its availability in India is not established here; hospitals elsewhere should check affected lots with pharmacy.
- Hospital pharmacies using premixed vancomycin bags should check lots against the FDA recall notice.
- Where bags are withdrawn, reconstituted vancomycin prepared by pharmacy is the usual substitute.
- Continue therapeutic drug monitoring as usual after any change in preparation.
- The recall concerns manufacturing practice, not vancomycin's efficacy.
Why it matters
Supply changes to a frequently used antibiotic need coordination between pharmacy and wards.
Don't overread it
A Class II manufacturing recall is administrative and does not signal a new safety concern with vancomycin.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free